In the News

Research in blood stem cells has revealed new information about how these cells decide what to become when they divide.

Scientists at the Sloan Kettering Institute have identified a fundamentally new type of protein-sorting system in cells.

A protein detected in the urine of children with Wilms’ tumor led to the development of a test to improve diagnosis and treatment.

Today, researchers from MSK Kids at Memorial Sloan Kettering Cancer Center (MSK) published results that examine elevated levels of a protein called prohibitin in the urine and tumors of children with Wilms’ tumors. Their findings could help doctors identify children who are at risk for disease recurrence and precisely tailor treatment to overcome drug resistance.

The discovery suggests a potential new treatment approach for certain cancers.

Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.

Hear from an MSK social worker about developing body confidence after cancer treatment.

Read why MSK’s medical team is the best in the nation at treating gynecologic cancers.

Memorial Sloan Kettering Cancer Center (MSK) has been ranked as the number two hospital for cancer care in the nation, according to <i>U.S. News & World Report</i> in its annual listing of Best Hospitals. Since the inception of the rankings 30 years ago, MSK has held either the first or second spot each year for cancer care. MSK was also ranked first in gynecology.

Memorial Sloan Kettering Cancer Center (MSK) researchers published new results that found that individuals with low-risk or intermediate-risk myeloma precursor disease known as monoclonal gammopathy of undetermined significance (MGUS) can convert to high-risk MGUS and progress to multiple myeloma within a five-year window. This research clinically supports recommendations for annual blood tests for all individuals diagnosed with MGUS along with re-assessments of a patient’s clinical-risk status. Their research was published today online in <i>JAMA Oncology</i>.